References: Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]

Views

CrossRef citations to date

Altmetric

References

Montrasio C, Cheli S, Clementi E. Pharmacogenetic practice of anticancer drugs: multiple approaches for an accurate and comprehensive genotyping. Pharmgenomics Pers Med. 2023;16:739–746. doi:10.2147/PGPM.S412430
PubMed Web of Science ®Google Scholar
Deac AL. Awareness and recommendation related to DPYD testing among medical oncologist in Romania: a survey study. Farmacia. 2023;71(4):841–847. doi:10.31925/farmacia.2023.4.21
Web of Science ®Google Scholar
EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine; 2020. Available from: https://www.ema.europa.eu/en/documents/press-release/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine_en.pdf. Accessed October 30, 2023.
Google Scholar
Roman YM. Pathway to ascertain the role of pharmacogenomics in healthcare utilization outcomes. Pharmgenomics Pers Med. 2021;14:379–380. doi:10.2147/PGPM.S309038
PubMed Web of Science ®Google Scholar
Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019;9(3):40. doi:10.3390/jpm9030040
PubMed Web of Science ®Google Scholar
De With M, Sadlon A, Cecchin E, et al. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. 2023. ESMO Open. 2023;8(2):101197. doi:10.1016/j.esmoop.2023.101197
PubMed Web of Science ®Google Scholar